News


Blood clot issue found in young COVID-19 patients at University Hospital

May 5, 2020

Clots in arms, legs, lungs, reported at University Hospital… SAN ANTONIO – University hospital is seeing a troubling trend when it comes to young people hospitalized with coronavirus. Even without having a predisposition for stroke, younger patients are still at risk for developing a deadly blood clot. So far, no one with coronavirus has suffered a […]




Five therapies for COVID-19 tried, tested at University Hospital

April 24, 2020

Doctors at University Hospital have launched an aggressive testing campaign of new drugs and treatments they hope will help them create a cocktail for COVID-19 cures in the future.   According to Dr. Diego Maselli, medical director of respiratory therapy at University Hospital, the repertoire for hospitalized treatment includes five drug approaches. Some are new, […]




Local conference organized by alumnus shares expertise about point-of-care ultrasound to physicians

March 5, 2020

Dr. Nilam Soni, alumnus of the M.S. in Clinical Investigation & Translational Science program, and professor of medicine at UT Health San Antonio helped organize the 10th annual Point-of-care Ultrasound Workshop held Feb. 14 to 15 in downtown San Antonio. Dr. Soni, is also the director of Point-of-Care Ultrasound Training of VHA SimLEARN, co-director of Medical […]




Meet the 2019-2020 CHEST President: Stephanie Levine, MD, FCCP

October 21, 2019

Stephanie Levine, MD, FCCP, is an expert in lung transplantation and pulmonary and critical care issues in pregnancy and women’s lung health. She is a Professor of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of Texas Health Science Center in San Antonio, Texas; the Program Director of the […]




Test for Deadly Lung Disease Is Used for First Time in Texas – Anoop Nambiar, MD

June 11, 2019

A UT Health San Antonio lung specialist is the first in Texas to use a new genomic test to better and less invasively diagnose a patient with idiopathic pulmonary fibrosis (IPF), a serious, chronic, progressive and scarring lung disease with an average survival time of less than five years after diagnosis…….Read more>>>>   Source: MD […]




Wear The Gown: Managing the rare disease of cystic fibrosis

May 28, 2019

SAN ANTONIO — There are 70,000 people in the world with cystic fibrosis. 30,000 of them are here in the U.S. In this Wear The Gown, we take you into the only “CF” clinic in San Antonio that takes care of patients from birth, all the way into adulthood. “Cystic fibrosis is a genetic disease […]




Medical News Today: Can we halt cellular aging? New drug combo shows promise

February 28, 2019

The story below features research Anoop Nambiar, M.D., M.S., on a new class of drugs called senolytics that were studied in relation to idiopathic pulmonary fibrosis. Dr. Nambiar is a professor of medicine and founding director of the Interstitial Lung Disease Program at UT Health San Antonio. Two other faculty members are mentioned in the […]



Woman beats potentially deadly disease after life-saving suggestion on social media

February 20, 2019

SAN ANTONIO — A local woman nearly lost her battle with a rare lung disease because it had gone undiagnosed. But it was her persistence to get help ultimately saved her life. Angela Michelle Ramos has a new lease on life. She’s working out and getting in shape; something that, until now, was out of […]



First-in-human trial of senolytic drugs encouraging

February 20, 2019

Small pilot study points to feasibility of larger trials in age-related diseases UT Health San Antonio researchers, collaborating with the Mayo Clinic and the Wake Forest School of Medicine, are the first to publish results on the treatment of a deadly age-related disease in human patients with drugs called senolytics. The findings were posted Jan. […]




Research update: New test for pulmonary fibrosis

February 19, 2019

A UT Health San Antonio lung specialist is the first in Texas to use a new genomic test to better and less invasively diagnose a patient with idiopathic pulmonary fibrosis (IPF), a serious chronic, progressive and scarring lung disease with an average survival time of less than five years after diagnosis.